|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Baseline CSP IgG levels are elevated in malaria cases than controls (p < 0.001).
|
31092823 |
2019 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, RhCMV strain 68-1 elicits CD8+ T cells broadly recognizing unconventional epitopes exclusively restricted by MHC-II and MHC-E. To evaluate the potential of these unique immune responses to protect against malaria, we expressed four Plasmodium knowlesi (Pk) antigens (CSP, AMA1, SSP2/TRAP, MSP1c) in RhCMV 68-1 or in Rh189-deleted 68-1, which additionally elicits canonical MHC-Ia-restricted CD8+ T cells.
|
30673723 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monthly entomological inoculation rates (EIR) that reflect malaria transmission dynamics were estimated by combining the HLC data with mosquito sporozoite infection rates (SIR) identified through ELISA-CSP.
|
30940141 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine sex differences in the efficacy of anti-sporozoite stage malaria vaccination, adult (10 weeks of age) or juvenile (11 days of age) male and female C3H mice were twice vaccinated with irradiated transgenic Plasmodium berghei sporozoites expressing the P. falciparum circumsporozoite (CSP) protein and 45 days post boost vaccination, mice were challenged with transgenic P. berghei via mosquito bite or intradermal challenge.
|
31262583 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predicting immunogenic regions in the proteome of the human malaria parasite <i>Plasmodium falciparum</i>, via the bioinformatics approach and subsequent array screening, confirmed known immunogenic sequences, such as in the leading malaria vaccine candidate CSP and discovered immunogenic epitopes derived from hypothetical or unknown proteins.
|
30630936 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
This represents an asset for malaria vaccine studies involving CSP-specific antibodies and selected antigens for sero-epidemiological purposes.
|
29843713 |
2018 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rodent malaria parasites where the gene encoding circumsporozoite protein (CSP) has been replaced with csp genes from the human malaria parasites, Plasmodium falciparum or Plasmodium vivax, are used as pre-clinical tools to evaluate CSP vaccines in vivo.
|
30092798 |
2018 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we report the development of a highly protective CSP-based P. vivax vaccine, a virus-like particle (VLP) known as Rv21, able to provide 100% sterile protection against a stringent sporozoite challenge in rodent models to malaria, where IgG2a antibodies were associated with protection in absence of detectable PvCSP-specific T cell responses.
|
28417968 |
2017 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To estimate the likelihood of success and to measure the outcome of malaria intervention tools during elimination programs (2008-2012), the population genetic surveys of Iranian P. vivax isolates (n=60) were carried out using the CSP genetic marker.
|
27102931 |
2016 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to extend our understanding of the epidemiology and evolutionary history of P. knowlesi, we examined 108 wild macaques for malaria parasites and sequenced the circumsporozoite protein (csp) gene and mitochondrial (mt) DNA of P. knowlesi isolates derived from macaques and humans.
|
21490952 |
2011 |